Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Abstract Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD-mineral and bone disorder. Currently, cinacalcet is indicated for the treatment of SHPT; however, cinacalcet...
Main Authors: | Keitaro Yokoyama, Ryutaro Shimazaki, Masafumi Fukagawa, Tadao Akizawa, On behalf of Evocalcet Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-019-42017-z |
Similar Items
-
Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
by: Tadao Akizawa, et al.
Published: (2018-01-01) -
Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
by: Shigematsu T, et al.
Published: (2018-09-01) -
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
by: Shigematsu T, et al.
Published: (2020-05-01) -
A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
by: Keitaro Yokoyama, et al.
Published: (2017-07-01) -
Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
by: Fumihiko Koiwa, et al.
Published: (2018-01-01)